Clinical toxicologic and pharmacologic studies of gallium nitrate.
Gallium nitrate, administered intravenously to patients with advanced cancer, produced renal functional abnormalities consistently at a dose of 750 mg/m2. The toxicity at that dose could be modified by fluid loading and osmotic diuresis. Pharmacokinetic studies revealed a biphasic half-life, (T 1/2 alpha = 87 minutes and T 1/2 beta = 24.5 hours). Osmotic diuresis reduced the urinary concentration of gallium but did not affect serum levels or clearance.
D000740:Anemia / Q000139:chemically induced; D002118:Calcium / Q000652:urine; D002986:Clinical Trials as Topic; D004231:Diuresis; D005708:Gallium / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D008353:Mannitol / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism
D008353:Mannitol; D005708:Gallium; D002118:Calcium